GSK plc (GLAXF)
OTCMKTS
· Delayed Price · Currency is USD
18.26
-0.51 (-2.72%)
Oct 30, 2024, 9:49 AM EDT
GSK plc Revenue
GSK plc had revenue of 8.01B GBP in the quarter ending September 30, 2024, a decrease of -1.66%. This brings the company's revenue in the last twelve months to 31.31B, up 5.59% year-over-year. In the year 2023, GSK plc had annual revenue of 30.33B with 3.42% growth.
Revenue (ttm)
31.31B GBP
Revenue Growth
+5.59%
P/S Ratio
n/a
Revenue / Employee
445.95K GBP
Employees
70,212
Market Cap
74.65B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
Dec 31, 2019 | 33.75B | 2.93B | 9.52% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.69B |
Ryman Healthcare Limited | 411.39M |
Verano Holdings Corp. | 920.97M |
Vireo Growth Inc. | 98.04M |
Medexus Pharmaceuticals Inc. | 108.78M |
GSK plc News
- 2 days ago - Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY - PRNewsWire
- 4 days ago - GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy' - Seeking Alpha
- 5 days ago - GSK stays in red for seven straight sessions - Seeking Alpha
- 6 days ago - Haleon: Too Vanilla For My Liking - I See Why GSK & Pfizer Wanted Out - Seeking Alpha
- 6 days ago - GSK reports positive data for RSV shot in younger, at-risk adults - Seeking Alpha
- 6 days ago - Companies Reporting: McDonalds, Aston Martin, GSK, Next - The Armchair Trader
- 6 days ago - Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer - Benzinga
- 6 days ago - New Data for AREXVY, GSK's Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease - Business Wire